Letter written in response to van Bon et al.: "insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial"

Diabetes Technology and Therapeutics

Volumn 13, Issue 8, 2011, Pages 869-870

  Jovanovič, Lois ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO;

BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG OVERDOSE; DRUG STABILITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE;

EID: 79960403328     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0122     Document Type: Letter

References (2)

1. van Bon AC, Bode BW, Sert-Langeron C, Devries JH, Charpentier G: Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2011;13:607-614.
2. Hoogma RP, Schumicki D: Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38:429-433. (Pubitemid 44047966)